The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Official Title: A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG)
Study ID: NCT05644561
Brief Summary: The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
Research Site, Chicago, Illinois, United States
Research Site, Chapel Hill, North Carolina, United States
Research Site, Akron, Ohio, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Marseille, , France
Research Site, PARIS Cedex 12, , France
Research Site, Milano, , Italy
Research Site, Roma, , Italy
Research Site, Torino, , Italy
Research Site, Itabashi-ku, , Japan
Research Site, Leiden, , Netherlands
Research Site, Belgrade, , Serbia
Research Site, Belgrade, , Serbia
Research Site, Madrid, , Spain
Research Site, Malaga, , Spain
Research Site, Bern, , Switzerland